Alzheimer’s Group Resources

Current Status Of The Development Programs Of New Indications And Formulations For Aricept(R) For Enhancing Patient Value

Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") and Eisai Corporation of North America (Headquarters: Woodcliff Lake, NJ, Chairman and CEO Hajime Shimizu) are currently focusing on three clinical development programs for the company's major product Aricept(R) (donepezil hydrochloride tablets) to further contribute to patients with Alzheimer's disease. As progress in those programs has been made, Eisai announces the status as follows: 1.

Read the original Alzheimer's Group Resources article at Alzheimer's / Dementia News From Medical News Today ...